Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
NCT04408794
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
974
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Migraine
Interventions
DRUG:
Zavegepant (BHV-3500)
Sponsor
Pfizer